Literature DB >> 11926379

Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.

June-Key Chung1, Yu Kyeong Kim, Seok-ki Kim, Yong Jin Lee, Suntta Paek, Jeong Seok Yeo, Jae Min Jeong, Dong Soo Lee, Hee Won Jung, Myung Chul Lee.   

Abstract

The fact that some brain tumors show hypo- or isometabolism on fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) has caused problems in the detection of primary or recurrent tumors and in the differentiation from benign lesions. We investigated the usefulness of carbon-11 methionine PET in characterizing brain lesions under these conditions. 11C-methionine PET was performed in 45 patients with brain lesions (in 34 for initial diagnosis and in 11 for detection of recurrence) that showed hypo- or isometabolism compared with normal brain tissue on FDG PET. Ten minutes after the injection of 555-740 MBq of 11C-methionine, attenuation-corrected brain images were obtained with a dedicated PET scanner. The brain lesions comprised 24 gliomas, five metastatic brain tumors, four meningiomas, two other brain tumors and ten benign lesions (including three cases of cysticercosis, two cases of radiation necrosis, one tuberculous granuloma, one hemangioma, one benign cyst, and one organizing infarction). Proliferative activity was measured using the Ki-67 immunostaining method in glioma tissues. Thirty-one of 35 brain tumors (89% sensitivity) showed increased 11C-methionine uptake despite iso- or hypometabolism on FDG PET. By contrast, all ten benign lesions showed decreased or normal 11C-methionine uptake (100% specificity). Twenty-two of 24 gliomas (92%) showed increased 11C-methionine uptake, the extent and degree of which exceeded 18F-FDG uptake, and the 11C-methionine uptake correlated with the proliferation index (r=0.67). The mean (+/-SD) uptake ratios of glioma to normal brain on FDG and 11C-methionine PET were 0.92+/-0.34 and 2.54+/-1.25, respectively. All metastatic tumors except one showed intense 11C-methionine uptake in the entire tumor or in the peripheral margin of the tumor. In meningiomas, 11C-methionine uptake showed a variable increase. In conclusion, brain lesions that show hypo- or isometabolism on FDG PET can be detected and differentiated with high sensitivity and good contrast using 11C-methionine PET. 11C-methionine PET can provide additional information when used in combination with FDG PET in the evaluation of these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11926379     DOI: 10.1007/s00259-001-0690-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  72 in total

1.  Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas.

Authors:  Michail Plotkin; C Blechschmidt; G Auf; F Nyuyki; L Geworski; T Denecke; W Brenner; F Stockhammer
Journal:  Eur Radiol       Date:  2010-06-03       Impact factor: 5.315

2.  Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.

Authors:  Johannes Schwarzenberg; Johannes Czernin; Timothy F Cloughesy; Benjamin M Ellingson; Whitney B Pope; Tristan Grogan; David Elashoff; Cheri Geist; Daniel H S Silverman; Michael E Phelps; Wei Chen
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

3.  [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.

Authors:  Seung Jin Choi; Jae Seung Kim; Jeong Hoon Kim; Seung Jun Oh; Jeong Gyo Lee; Chang Jin Kim; Young Shin Ra; Jeong Seok Yeo; Jin Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02-15       Impact factor: 9.236

4.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.

Authors:  Osamu Manabe; Naoya Hattori; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Tohru Shiga; Keiichi Magota; Noriko Oyama-Manabe; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

5.  PET imaging in pediatric neuroradiology: current and future applications.

Authors:  Sunhee Kim; Noriko Salamon; Hollie A Jackson; Stefan Blüml; Ashok Panigrahy
Journal:  Pediatr Radiol       Date:  2009-11-24

Review 6.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

7.  Usefulness of ¹¹C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions.

Authors:  Atsushi Watanabe; Yoshihiro Muragaki; Takashi Maruyama; Jun Shinoda; Yoshikazu Okada
Journal:  J Neurooncol       Date:  2015-11-26       Impact factor: 4.130

8.  18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT.

Authors:  Sellam Karunanithi; Punit Sharma; Abhishek Kumar; Bangkim Chandra Khangembam; Guru Pada Bandopadhyaya; Rakesh Kumar; Deepak Kumar Gupta; Arun Malhotra; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-23       Impact factor: 9.236

Review 9.  11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas.

Authors:  Tarun Singhal; Tanjore K Narayanan; Viney Jain; Jogeshwar Mukherjee; Joseph Mantil
Journal:  Mol Imaging Biol       Date:  2007-10-24       Impact factor: 3.488

10.  Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury.

Authors:  Patrick A Hein; Clifford J Eskey; Jeffrey F Dunn; Eugen B Hug
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.